The Clinical Scholars Biomedical Research Training Program at Memorial Sloan-Kettering Cancer Center (MSKCC) provides a mentored laboratory training experience in cancer research for a group of outstanding MD's or MD/PhD's. This training will prepare highly qualified physician-scientists for a career at the interface of cancer biology and clinical research. Six positions are requested. The fellows are trained by principal investigators, drawn from the professional staff of Memorial Sloan-Kettering Cancer Center who are laboratory investigators. A structured and cohesive two-year training program has been designed to provide outstanding mentorship in guided laboratory research, didactic course work in modern biology and bioinformatics and career development skills. Trainees have access to all resources of the Memorial Sloan-Kettering Cancer Center. The areas of principal emphasis for research include: 1) Signals and pathways involved in control of cell proliferation;2) Regulatory pathways involved in developmental biology and cell differentiation;3) Cell-cell interactions, adhesion and protein targeting;4) Tumor immunology, immunotherapy and transplantation biology;5) Human cancer biology, mouse models of cancer, genetics and molecular pathology;and 6) Drug development and therapeutics. Physicians-scientists receiving training from this program will be poised to more readily translate the recent revolutionary discoveries of biomedical, cancer-related research into patient care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009512-28
Application #
8705400
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Lim, Susan E
Project Start
1985-02-01
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
28
Fiscal Year
2014
Total Cost
Indirect Cost
City
New York
State
NY
Country
United States
Zip Code
10065
Sharma, Sai Kiran; Chow, Andrew; Monette, Sebastien et al. (2018) Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Cancer Res 78:1820-1832
Untch, Brian R; Dos Anjos, Vanessa; Garcia-Rendueles, Maria E R et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Res 78:4642-4657
Maus, Marcela V; Plotkin, Jason; Jakka, Gopinadh et al. (2016) An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol Ther Oncolytics 3:1-9
Viny, Aaron D; Ott, Christopher J; Spitzer, Barbara et al. (2015) Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. J Exp Med 212:1819-32
Callahan, Margaret K; Masters, Gregg; Pratilas, Christine A et al. (2014) Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res 2:70-9
Snyder, Alexandra; Makarov, Vladimir; Merghoub, Taha et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199
Diab, Adi; Jenq, Robert R; Rizzuto, Gabrielle A et al. (2013) Enhanced responses to tumor immunization following total body irradiation are time-dependent. PLoS One 8:e82496
Rizzuto, Gabrielle A; Merghoub, Taha; Hirschhorn-Cymerman, Daniel et al. (2009) Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206:849-66
Marcucci, Guido; Maharry, Kati; Radmacher, Michael D et al. (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 26:5078-87
Perales, M-A; Ishill, N; Lomazow, W A et al. (2007) Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 40:481-6

Showing the most recent 10 out of 115 publications